It actually says overexpression of CCR5 is a posit
Post# of 154635
(Total Views: 706)
Posted On: 11/05/2021 8:23:32 AM
Re: Goosebumps #109817
It actually says overexpression of CCR5 is a positive in cancer suppression.
They then go on to say it's applicable to a variety of cancers.
They try to apply any positives of CCR5 overexpression and TP53 mutation (TP53 is a tumor suppressor the mutation decreases it) to a number of cancers. The TP53 mutation is fairly rare.
They cite a paper that said CCR5 delta 32 decreased life expectancy that was withdrawn because of erroneous data.
But the biggest problem is that it looks like they took a bunch of data sets to try and prove the wider point that CCR5 overexpression is good for a wider variety of cancers but may only prove it with the TP53 mutation.
https://www.aging-us.com/article/203654/text
Quote:
CCR5 is associated with better survival of TNBC patients with TP53 mutation, which may exert its roles through tumor immune environment.
They then go on to say it's applicable to a variety of cancers.
Quote:
We and our collaborators showed that CCR5 overexpression was associated with better prognosis of breast cancer, lung cancer, liver cancer, rectal cancer and cervical cancer which might owing to its association with immune cell infiltration
They try to apply any positives of CCR5 overexpression and TP53 mutation (TP53 is a tumor suppressor the mutation decreases it) to a number of cancers. The TP53 mutation is fairly rare.
Quote:
Our results indicated that CCR5 is associated with longer OS of TNBC patients with TP53 mutation and is positively correlated with tumor immune response. These results seem to be inconsistent with Pestell’s results, which could be explained by drawbacks of their experiment design that merely using cancer cell lines and immunodeficient (NOD/SCID) mice model.
They cite a paper that said CCR5 delta 32 decreased life expectancy that was withdrawn because of erroneous data.
Quote:
It was reported that CCR5-Δ32/Δ32 genotype was associated with reduced life expectancy despite the protective effect of the mutation against HIV by analyzing genotyping and death registry information of 409,693 individuals of British ancestry [7].
But the biggest problem is that it looks like they took a bunch of data sets to try and prove the wider point that CCR5 overexpression is good for a wider variety of cancers but may only prove it with the TP53 mutation.
Quote:
In this study, we will analysis the expression and prognostic value of CCR5 in TNBC and explore the underlying molecular mechanisms using multi-omics data.
https://www.aging-us.com/article/203654/text
(9)
(0)